Trials / Enrolling By Invitation
Enrolling By InvitationNCT05612061
Indigenous Recovery Planning for American Indians
Randomized Controlled Trial of Indigenous Recovery Planning for American Indians
- Status
- Enrolling By Invitation
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Montana State University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research project uses a Community-Based Participatory Research (CBPR) framework to test the efficacy of a culturally adapted relapse prevention intervention developed collaboratively by community partners from the Fort Peck Indian Reservation in northeastern Montana and research partners from Montana State University. The Indigenous Recovery Planning intervention employs trained Fort Peck community members to deliver manualized intervention content to American Indian adults with substance use disorder (SUD). By increasing access to culturally responsive evidence-based treatment, this research aims to decrease SUD-related health disparities and improve public health outcomes for underserved Native communities locally and nationally.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Indigenous Recovery Planning | The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use. Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future. |
Timeline
- Start date
- 2022-11-02
- Primary completion
- 2026-02-01
- Completion
- 2026-02-01
- First posted
- 2022-11-10
- Last updated
- 2025-07-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05612061. Inclusion in this directory is not an endorsement.